[go: up one dir, main page]

PE20001338A1 - Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c - Google Patents

Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c

Info

Publication number
PE20001338A1
PE20001338A1 PE1999001306A PE00130699A PE20001338A1 PE 20001338 A1 PE20001338 A1 PE 20001338A1 PE 1999001306 A PE1999001306 A PE 1999001306A PE 00130699 A PE00130699 A PE 00130699A PE 20001338 A1 PE20001338 A1 PE 20001338A1
Authority
PE
Peru
Prior art keywords
interleuquin
virus
treatment
hepatic
hepatitis
Prior art date
Application number
PE1999001306A
Other languages
English (en)
Inventor
Paul C Grint
David R Nelson
Gary L Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20001338A1 publication Critical patent/PE20001338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL USO DE INTERLEUQUINA 10 HUMANA O VIRAL Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS C CRONICA; AL MEJORAR LA HISTOLOGIA HEPATICA, PREVENIR LA LESION HEPATICA DEL PACIENTE, FIBROSIS HEPATICA, MEJORAR LA FUNCION HEPATICA, MODULAR LA RESPUESTA INFLAMATORIA Y EL PROCESO DE FIBROSIS RESPONSABLE DE LA DESTRUCCION DEL HIGADO. TAMBIEN SE REFIERE AL USO ADEMAS DE INTERFERON O-2a, O-2b, INTERFERON O 2a o 2b PEG MODIFICADO Y RIBAVIRINA
PE1999001306A 1998-12-22 1999-12-21 Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c PE20001338A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21884298A 1998-12-22 1998-12-22
US29374299A 1999-04-16 1999-04-16
US42571699A 1999-10-22 1999-10-22

Publications (1)

Publication Number Publication Date
PE20001338A1 true PE20001338A1 (es) 2000-12-06

Family

ID=27396589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001306A PE20001338A1 (es) 1998-12-22 1999-12-21 Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c

Country Status (7)

Country Link
US (1) US6685931B1 (es)
EP (1) EP1140142A2 (es)
JP (1) JP2002532556A (es)
AU (1) AU2158000A (es)
CA (1) CA2356010A1 (es)
PE (1) PE20001338A1 (es)
WO (1) WO2000037096A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100448993C (zh) * 2000-06-30 2009-01-07 津莫吉尼蒂克斯公司 干扰素样蛋白质Zcyto21
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
BR0114636A (pt) * 2000-10-18 2004-02-10 Schering Corp Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) * 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
RU2286792C1 (ru) * 2005-03-05 2006-11-10 Александр Исаакович Венгеровский Способ лечения хронических гепатитов
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2010149767A1 (en) * 2009-06-25 2010-12-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining the risk of occurence of liver fibrosis in an individual
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2937088B1 (en) 2012-12-21 2020-11-18 Tokushima University Composition having tissue repairing activity and utilization thereof
US9943568B2 (en) * 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3341012B1 (en) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740552A1 (en) * 1994-01-20 1996-11-06 Schering Corporation Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
EP1013764A1 (en) * 1994-07-05 2000-06-28 Steeno Research Group A/S Immunomodulators
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
JP2000507917A (ja) 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
EP0906117A1 (en) * 1996-05-02 1999-04-07 Schering Corporation Method for treating or preventing ischemia-reperfusion injury

Also Published As

Publication number Publication date
JP2002532556A (ja) 2002-10-02
US6685931B1 (en) 2004-02-03
WO2000037096A3 (en) 2000-11-30
WO2000037096A2 (en) 2000-06-29
AU2158000A (en) 2000-07-12
EP1140142A2 (en) 2001-10-10
CA2356010A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
PE20001338A1 (es) Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
BR0111195A (pt) Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
RU94022480A (ru) Способ лечения гепатита, композиция, усиливающая ин виво инактивацию вируса гепатита с, препарат для лечения гепатита с
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
CO5050297A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
EA200400962A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
ATE500808T1 (de) Onkolytische virustherapie
BR9810745A (pt) Derivados de benzimidazol
TR200003113T2 (tr) 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
AR023541A1 (es) Terapia de combinacion para vhc
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
DE69932510D1 (de) Vaskularisierungsinhibitoren
ATE405261T1 (de) Verwendung von castanospermine derivaten in der behandlung von hepatitis c
EP1256348A4 (en) REMEDIES AGAINST HEPATITIS
ATE394104T1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
CL2004000261A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica.
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso
DE69718156D1 (de) Polypflanzliche pharmazeutische Zusammensetzungen geeignet in der Behandlung der Hepatitis E und Hepatitis B Virus-Infektion zusammenhängenden Zustände
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections

Legal Events

Date Code Title Description
FC Refusal